, Tracking Stock Market Picks
Enter Symbol:
Affymax, Inc. (AFFY) [hlAlert]

down 99.53 %

Affymax, Inc. (AFFY) rated Buy with price target $29 by Stanford Research

Posted on: Wednesday,  Sep 24, 2008  9:25 AM ET by Stanford Research

Stanford Research rated Buy Affymax, Inc. (OTCBB: AFFY) on 09/24/2008, when the stock price was $18.53. Since
then, Affymax, Inc. has lost 99.54% as of 08/27/2015's recent price of $0.09.
If you would have followed this Stanford Research's recommendation on AFFY, you would have lost 99.53% of your investment in 2528 days.

Affymax, Inc. is a biopharmaceutical company developing peptide-based drugs to improve the treatment of serious and often life-threatening conditions. The Company's product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a relatively small synthetic peptide-based erythropoiesis stimulating agent (ESA), which it is developing for the treatment of anemia patients with chronic renal failure. The Company is conducting Phase III clinical trials in patients suffering from chronic renal renal failure, on dialysis and not on dialysis (pre-dialysis). In August 2008, the Company and Takeda Pharmaceutical Company Limited (Takeda), agreed to suspend development of Hematide to treat chemotherapy induced anemia.

Stanford Research encompasses both institutional equity research and Washington-focused policy research, offering a perspective on individual companies, sector-specific topics and national policy. The importance Stanford Group Company places on research comes from years of experience in a constantly changing world. We know that as markets develop and new sectors grow, it is imperative that our clients have the most accurate information available to ensure financial success. Stanford Group Company clients will always have our commitment to conduct informative and enlightening research. As a part of our commitment to our clients, we provide objective, well-developed research. Our skilled analysts use their talent to provide invaluable research that can help in making important decisions. Thanks to a wide range of resources obtained through technology, experience and reputation, our research analysts develop reports on the most current firms and sectors. Our equity analysts offer insight and opinions on companies in the consumer/retail, media, energy, financial institutions, health care, technology and water/environment sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2008 9:25 AM Buy
18.53 29.00
as of 12/24/2008
1 Week down  -3.73 %
1 Month up  9.24 %
3 Months up  72.67 %
1 YTD up  72.67 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy